NCT06121466 Effect of Abdominal Wall Injections on Abdominal Pain
| NCT ID | NCT06121466 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Oregon Health and Science University |
| Condition | Anterior Cutaneous Nerve Entrapment Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 45 participants in total. It began in 2023-01-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective cohort study of outpatient adults with chronic abdominal wall pain receiving abdominal wall injections, as part of their usual care, with lidocaine. Subjects will be recruited at the outpatient gastroenterology clinic at OHSU.
Eligibility Criteria
Inclusion Criteria: * Localized abdominal wall pain * Average daily pain (7-day recall) ≥ 3 on a scale of 0-10 * Suspected abdominal wall etiology for abdominal pain * Positive Carnett's sign or pain near an incisional site * 18 years of age or older Exclusion Criteria: * Suspected visceral etiology for the abdominal pain * Severe allergy to lidocaine * Unwillingness or inability to provide informed consent * Low probability of follow-up * Abdominal wall hernia noted at the point of pain * History of trigger point injections for abdominal pain * Bleeding disorder * Pregnancy, incarceration or decisionally impaired
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06121466 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Anterior Cutaneous Nerve Entrapment Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06121466 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06121466 currently recruiting?
Yes, NCT06121466 is actively recruiting participants. Contact the research team at lichenst@ohsu.edu for enrollment information.
Where is the NCT06121466 trial being conducted?
This trial is being conducted at Portland, United States, Portland, United States.
Who is sponsoring the NCT06121466 clinical trial?
NCT06121466 is sponsored by Oregon Health and Science University. The trial plans to enroll 45 participants.